Atnaujinkite slapukų nuostatas

El. knyga: Targeted Therapy of Acute Myeloid Leukemia

Edited by
  • Formatas: PDF+DRM
  • Serija: Current Cancer Research
  • Išleidimo metai: 20-Nov-2014
  • Leidėjas: Springer-Verlag New York Inc.
  • Kalba: eng
  • ISBN-13: 9781493913930
Kitos knygos pagal šią temą:
Targeted Therapy of Acute Myeloid LeukemiaDidesnis paveikslėlis
  • Formatas: PDF+DRM
  • Serija: Current Cancer Research
  • Išleidimo metai: 20-Nov-2014
  • Leidėjas: Springer-Verlag New York Inc.
  • Kalba: eng
  • ISBN-13: 9781493913930
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

This book provides an unprecedented overview of "Targeted Therapies" for acute myeloid leukemias. It aims at an almost comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Paired and authoritative chapters by leading research scientists and clinicians explain basic concepts and clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML, the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53 and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. Chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells and leukemia metabolism provide insights into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies round up this overview of the multi-dimensional therapeutic landscape in which leukemia specialists develop treatment strategies that are expected to make "leukemia history" in the near future.
Introduction/Perspective.- Genetics and Classification of Acute Myeloid
Leukemia.- Proteomics of AML to guide Selection of Therapy.- Roles of
Apoptosis Regulating Bcl-2-Family Genes in AML.- Bcl-2 family: Translational
aspects.- IAP Family and Proteins as Therapeutic Targets for Acute Myeloid
Leukemia.- TP53 Mutations in Acute Myeloid Leukemia.- Targeting p53 Tumor
Suppressor for AML Therapy.- AML-Selective Apoptosis Induction by rationally
designed Death Ligand Fusion Protein.- PIM Kinases in AML.- Development of
Midostaurin as a Tyrosine Kinase Inhabitor.- FLT3 in AML.- FLT3-ITD. Clinical
(Sorafenib/AC220).- Nucleophosmin (NPM1).- Raf/MEK Pathway.- The Role of
Translational Medicine in Optimization of Therapies targeting the RAS-MAP
Kinase Pathway.- Clinical Use of Farnesyltransferase Inhititors.- The
P13K-AKT-mTOR signaling Network in AML.- Targeting the P13 Kinase-mTOR
Signaling Pathway in AML.- Aurora kinases.- The Clinical Development of
Aurora Kinase Inhibitors in Acute Myeloid Leukemia.- AML-Deacetylases.-
Methylation in AML-Clinical Applications.- Topic: RARa/RXR  Part: Basic.-
Arsenic Trioxide in Untreated APL.- Targeting PML-RAR with Retinoids.- NR4A
Orphan Receptors as Drug Targets.- Antibody-based Therapeutics Targeting
CD33, CD45, and CD66.- New Heterogeneity of the Leukemic Stem Cells.-
Targeting Leukemia Stem Cells.- Regulation of Hematopoiesis by CXCL12/CXCR4
Signaling.- CXC4/CXCL12 as a Therapeutic Target.- VLA-4: A Cells
Consequential Encounter.- VLA-4 Function and Prognosis in Acute Myeloid
Leukemia.- VLA4 in Acute Lymphoblastic Leukemia.- The Leukemic Bone Marrow
Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-Drugs.- Topic:
miRs as Therapeutic Targets.- Clinical Implications of MicroRNAs in AML.-
Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid
Leukemias.- Molecular and Biochemical Basis for the Reprogramming of
Intermediary Metabolism in Leukemia Cells.- NK Cell Immunotherapy for AML.-
Allogeneicand Autologous T cell Strategies to Enhance Targeting of Acute
Myeloid Leukemia.- Indications for Hematopoietic Transplantation for AML.-
Mesenchymal Stem/Stromal Cell Targeted Therapies for Solid Tumors and
Hematological Malignancies.
Daugiau apie elektronines knygas Daugiau apie elektronines knygas
Pastovi nuoroda: https://www.kriso.lt/db/97814939139302e.html
Raktažodžiai: